Impact of genetic markers on treatment of non-small cell lung cancer

Nicholas Lamparella, Amit Barochia, Salah Almokadem

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Scopus citations

Abstract

Non-small cell lung cancer represents a group of heterogeneous diseases. The last decade witnessed significant progress in improving our understanding of the biology of non-small cell lung cancer, which led to the identification of several genetic targets. Those genetic targets were utilized to explain clinical phenomena, such as the occurrence of non-small cell lung cancer in never-smokers, to predict response to conventional chemotherapy and biological agents, and to explain and predict resistance to therapy. The progress in the treatment of non-small cell lung cancer in the last few years was based on a new generation of population-enriched clinical trials that utilized genetic targets such as somatic EGFR mutations and ALK-EML4 mutations. In this review we will discuss the available information about the key genetic markers of non-small cell lung cancer and the pivotal clinical trials that validate the use of those genetic markers in non-small cell lung cancer patients.

Original languageEnglish (US)
Title of host publicationImpact of Genetic Targets on Cancer Therapy
EditorsWafik El-Deiry
Pages145-164
Number of pages20
DOIs
Publication statusPublished - Feb 15 2013

Publication series

NameAdvances in Experimental Medicine and Biology
Volume779
ISSN (Print)0065-2598

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Lamparella, N., Barochia, A., & Almokadem, S. (2013). Impact of genetic markers on treatment of non-small cell lung cancer. In W. El-Deiry (Ed.), Impact of Genetic Targets on Cancer Therapy (pp. 145-164). (Advances in Experimental Medicine and Biology; Vol. 779). https://doi.org/10.1007/978-1-4614-6176-0-6